ChemBriefNovartis to acquire UK-based Myricx Bio for up to $1.5 billion
Novartis agreed to acquire UK biotech Myricx Bio for up to $1.5 billion to expand its antibody-drug conjugate cancer treatments, with the deal set to close in the second half of 2026.
reuters · 2026-07-05 22:26